Heyburn William A. sold $186K of SRTA

Heyburn William A. (Co-CEO and CFO) sold 31,671 shares of Strata Critical Medical, Inc. (SRTA) at $5.87 ($0.19M total) on 2026-06-08.

Original reporting
SEC EDGAR · Heyburn William A.
Published Jun 10, 2026, 8:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SRTA
Bearish
medium confidence
Mentioned
$SRTA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SRTABearishLow
01

Why it matters

Top executive selling can influence short-term sentiment, but traders typically need corroborating fundamental news (earnings, guidance, trial/regulatory updates) to reprice the stock materially.

02

Market read

Provides a fresh, primary-source datapoint of insider selling at a specific price and date; useful for sentiment/positioning checks rather than a standalone catalyst.

03

What to watch

The filing does not state intent, liquidity needs, or whether other insiders/large holders are buying; without follow-on transactions, signal-to-noise is low.

Relevance 4/10Novelty 8/10Timing: filed 2026-06-10 (sale dated 2026-06-08)

Background

The article is an SEC Form 4 insider transaction disclosure for Strata Critical Medical, Inc.

Company-level read

Ticker impact

$SRTABearishMedium confidence
Context

Strata Critical Medical disclosed a Form 4 showing Co-CEO/CFO Heyburn William A sold 31,671 shares at $5.87 on 2026-06-08.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than fundamentals.

Evidence & confidence

The article is a primary-source insider transaction (Form 4) with a defined sale size and price, but it provides no new business, guidance, or regulatory/contract catalyst.

Market effects

Minimal; this is company-specific insider activity with no sector-wide datapoint.

None indicated.

None indicated.

Counterpoint

A non-10b5-1 pre-arranged plan is not used here, but insider sales can be driven by diversification/taxes rather than bearish fundamentals.

Key entities

  • Strata Critical Medical, Inc.

    Company whose insider transaction was disclosed on SEC Form 4.

  • Heyburn William A.

    Co-CEO and CFO who sold 31,671 shares at $5.87 on 2026-06-08.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SRTAMed

Strata Critical Medical (SRTA) Q3 2026 Earnings Call Transcript

Strata Critical Medical (SRTA) reported Q3 2026 earnings, exceeding guidance with 20% sequential revenue growth in clinical services, $8.6M in free cash flow, and $42M in cash. The company announced a $20M share repurchase program and expects high-teens organic EBITDA growth in 2027. Strata completed acquisitions and aims to deploy additional capital strategically.

$SRTAMed

Strata Critical Medical Q3 Earnings Call Highlights

Strata Critical Medical (SRTA) reported Q3 clinical gross profit up 18.3% sequentially, but gross margin declined to 25.6%. Logistics revenue fell 6.9% sequentially, while gross margin improved to 20.8%. The company expects higher margins in 2027. Strata ended the quarter with $41.6M in cash and authorized a $20M share repurchase. It reiterated 2026 guidance and expects high-teens organic adjusted EBITDA growth in 2027.

$SRTAMed

Strata Critical Medical Announces Third Quarter 2026 Results

Strata Critical Medical, Inc. (SRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 November 3, 2026 Strata Critical Medical Announces Third Quarter 2026 Results • Revenue increased 50.3% year-over-year to $74.1 million in Q3 2026 • Clinical revenue increased 20.3% sequentially in Q3 2026 vs Q2 2026 • Q3 2026 net loss from continuing operations of $

$SRTAMedAI 8/10

Strata Critical Medical (SRTA) Q2 2026 Earnings Call Transcript

Strata Critical Medical (SRTA) reported Q2 2026 results, citing 15.1% sequential organic clinical revenue growth, with Transplant Clinical up 23.8%. Clinical gross margin rose to 26.1%. It generated $5.7M operating cash flow and $2.9M free cash flow. The company completed three bolt-on acquisitions and expects stronger cash generation in H2.

$SRTAMed

Strata Critical Medical Announces Second Quarter 2026 Results

Strata Critical Medical, Inc. (SRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 August 4, 2026 Strata Critical Medical Announces Second Quarter 2026 Results • Revenue increased 60.7% year-over-year to $72.5 million in Q2 2026 • Clinical revenue increased 22.6% sequentially in Q2 2026; Excluding Clinical acquisitions that closed in Q2 2026, Clini